<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772612</url>
  </required_header>
  <id_info>
    <org_study_id>516-012</org_study_id>
    <nct_id>NCT04772612</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe&#xD;
      Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - AUClast (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>AUC from time zero to the last measured time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Tmax (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Time to reach maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC∞ (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinity moderate, or severe hepatic impairment compared to control subjects with normal hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - t1/2 (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - CL/F (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Apparent total plasma clearance when dosed orally</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Vz/F (sitravatinib)</measure>
    <time_frame>9 days</time_frame>
    <description>Apparent volume of distribution when dosed orally</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - fu (sitravatinib)</measure>
    <time_frame>days 1 - 4</time_frame>
    <description>Unbound fraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From the time the ICF is signed until 14 ± 2 days after the last dose of sitravatinib treatment</time_frame>
    <description>Incidence and severity of adverse events (AEs).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Sitravatinib in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitravatinib in subjects with mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitravatinib in subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitravatinib in subjects with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitravatinib</intervention_name>
    <description>sitravatinib</description>
    <arm_group_label>Sitravatinib in healthy subjects</arm_group_label>
    <arm_group_label>Sitravatinib in subjects with mild hepatic impairment</arm_group_label>
    <arm_group_label>Sitravatinib in subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Sitravatinib in subjects with severe hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, between 18 and 75 years of age, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          -  Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.&#xD;
&#xD;
          -  Females of childbearing potential will not be pregnant or lactating and must have a&#xD;
             negative result on an approved pregnancy test at screening and check-in. Females of&#xD;
             childbearing potential must agree to use contraception by a method of proven&#xD;
             reliability (including abstinence) as detailed in the protocol.&#xD;
&#xD;
          -  Male subjects must agree to use contraception as detailed in the protocol.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Participants with normal hepatic function must also satisfy the following criteria:&#xD;
&#xD;
        - Participants with normal hepatic function must be in good health, determined by no&#xD;
        clinically significant findings from medical history, physical examination, 12-lead ECG,&#xD;
        vital signs measurements, or clinical laboratory evaluations at screening and check-in as&#xD;
        assessed by the investigator.&#xD;
&#xD;
        Participants with hepatic impairment must also satisfy the following criteria:&#xD;
&#xD;
        - Participants must meet the criteria for mild, moderate, or severe hepatic impairment&#xD;
        based on Child Pugh (CP) score and classification as detailed in the protocol.&#xD;
        Hepatically-impaired participants will be assigned to groups according to CP scores&#xD;
        calculated at screening; CP scores will be recalculated at check-in to confirm that&#xD;
        subjects do not have significant changes in status to ensure subject safety for the study,&#xD;
        as determined by the investigator and medical monitor.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal,&#xD;
             neurological, respiratory, endocrine, or psychiatric disorder, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  History of intestinal disease, inflammatory bowel disease, major gastric surgery, or&#xD;
             other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption&#xD;
             syndrome) likely to alter absorption of study treatment or result in inability to&#xD;
             swallow oral medications (Cholecystectomy is not allowed.).&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever&#xD;
             is longer.&#xD;
&#xD;
          -  Participants who, in the opinion of the investigator, should not participate in this&#xD;
             study.&#xD;
&#xD;
        Participants with normal hepatic function will be excluded from the study if any of the&#xD;
        following criteria are applicable:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any hepatic disease, as determined by&#xD;
             lab abnormalities: AST, ALT, alkaline phosphatase, or alpha-fetoprotein &gt;1 × upper&#xD;
             limit of normal or as deemed clinically significant by the investigator.&#xD;
&#xD;
          -  Participant has creatinine clearance &lt;80 mL/minute as calculated by using the&#xD;
             Cockcroft-Gault equation.&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products within 14 days prior to&#xD;
             dosing, unless deemed acceptable by the investigator, medical monitor, and sponsor.&#xD;
&#xD;
        Participants with hepatic impairment will be excluded from the study if any of the&#xD;
        following criteria are applicable:&#xD;
&#xD;
          -  Ventricular dysfunction or history of risk factors for Torsades de Pointes (eg,&#xD;
             unexplained syncope, known long QT syndrome, heart failure, and cardiomyopathy).&#xD;
&#xD;
          -  Participant has had a change in disease status within 90 days prior to the study drug&#xD;
             administration on Day 1, as documented by the subject's medical history, deemed&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
          -  Participant has required a new medication or a change in medication dose within 2&#xD;
             weeks before dosing with sitravatinib.&#xD;
&#xD;
          -  Participant has a current functioning organ transplant or is waiting for an organ&#xD;
             transplant.&#xD;
&#xD;
          -  History of unstable diabetes mellitus as evidenced by hemoglobin A1c ≥9% at screening.&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (&gt; 150 mm Hg systolic or &gt;100 mm Hg diastolic) on&#xD;
             multiple observations despite standard of care treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>1-844-893-5530</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Goerlitz</last_name>
      <email>debra.goerlitz@ocresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisela Seni</last_name>
      <phone>305-817-2900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Brown</last_name>
      <phone>407-240-7878</phone>
      <email>cindy.brown@ocrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bookey</last_name>
      <phone>651-641-2902</phone>
      <email>j.bookey@nucleusnetwork.com</email>
    </contact>
    <investigator>
      <last_name>Jolene Berg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilio De La Garza</last_name>
      <email>cdelagarza@txliver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

